Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours.
Date
2023-08-30ICR Author
Author
Legrand, AJ
Choul-Li, S
Villeret, V
Aumercier, M
Type
Journal Article
Metadata
Show full item recordAbstract
ETS transcription factors are a highly conserved family of proteins involved in the progression of many cancers, such as breast and prostate carcinomas, Ewing's sarcoma, and leukaemias. This significant involvement can be explained by their roles at all stages of carcinogenesis progression. Generally, their expression in tumours is associated with a poor prognosis and an aggressive phenotype. Until now, no efficient therapeutic strategy had emerged to specifically target ETS-expressing tumours. Nevertheless, there is evidence that pharmacological inhibition of poly(ADP-ribose) polymerase-1 (PARP-1), a key DNA repair enzyme, specifically sensitises ETS-expressing cancer cells to DNA damage and limits tumour progression by leading some of the cancer cells to death. These effects result from a strong interplay between ETS transcription factors and the PARP-1 enzyme. This review summarises the existing knowledge of this molecular interaction and discusses the promising therapeutic applications.
Collections
Subject
DNA damage
ETS transcription factors
PARP-1
cancer therapy
pharmacological inhibition
Humans
Leukemia
Poly Adenosine Diphosphate Ribose
Poly(ADP-ribose) Polymerase Inhibitors
Prostatic Neoplasms
Sarcoma, Ewing
Research team
Convergence SC Management
Language
eng
Date accepted
2023-08-28
License start date
2023-08-30
Citation
International Journal of Molecular Sciences, 2023, 24 (17), pp. 13454 -
Publisher
MDPI